blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3694853

EP3694853 - PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.03.2024
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  14.04.2023
FormerGrant of patent is intended
Status updated on  07.12.2022
FormerExamination is in progress
Status updated on  30.04.2021
FormerRequest for examination was made
Status updated on  17.07.2020
FormerThe international publication has been made
Status updated on  19.04.2019
Formerunknown
Status updated on  13.11.2018
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): BE		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
For all designated states
Loxo Oncology, Inc.
Lilly Corporate Centre
Indianapolis
Indiana 46285 / US
[2023/20]
Former [2020/34]For all designated states
Array BioPharma Inc.
3200 Waltnut Street
Boulder, CO 80301 / US
For all designated states
Loxo Oncology, Inc.
Lilly Corporate Centre
Indianapolis
Indiana 46285 / US
Inventor(s)01 / EARY, Charles Todd
4214 DaVinci Drive
Longmont, CO 80503 / US
02 / SPENCER, Stacey
c/o Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
03 / CRANE, Zack
2620 Trade Centre Ave.
Longmont, CO 80503 / US
04 / CHANDO, Katelyn
2620 Trade Centre Ave.
Longmont, CO 80503 / US
05 / ASSELIN, Sylvie
2620 Trade Centre Ave.
Longmont, CO 80503 / US
06 / LIU, Weidong
2620 Trade Centre Ave.
Longmont, CO 80503 / US
07 / WELCH, Mike
2620 Trade Centre Ave.
Longmont, CO 80503 / US
08 / COOK, Adam
c/o Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
09 / KOLAKOWSKI, Gabrielle R.
c/o Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
10 / METCALF, Andrew T.
c/o Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
11 / MORENO, David A.
c/o Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
12 / TANG, Tony P.
c/o Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301 / US
 [2020/34]
Representative(s)Smith, Andrew George
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU / GB
[2023/20]
Former [2020/34]Smith, Andrew George
Eli Lilly and Company Limited European Patent Operations Lilly Research Centre Erl Wood Manor
Windlesham, Surrey GU20 6PH / GB
Application number, filing date18796238.610.10.2018
[2020/34]
WO2018US55255
Priority number, dateUS201762570565P10.10.2017         Original published format: US 201762570565 P
[2020/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019075092
Date:18.04.2019
Language:EN
[2019/16]
Type: A1 Application with search report 
No.:EP3694853
Date:19.08.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 18.04.2019 takes the place of the publication of the European patent application.
[2020/34]
Type: B1 Patent specification 
No.:EP3694853
Date:17.05.2023
Language:EN
[2023/20]
Search report(s)International search report - published on:EP18.04.2019
ClassificationIPC:C07D471/04, C07D519/00
[2020/34]
CPC:
C07D519/00 (EP,US); C07D471/04 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/34]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERFAHREN ZUR HERSTELLUNG VON 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDIN-3-CARBONITRIL[2020/34]
English:PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE[2020/34]
French:PROCÉDÉ DE PRÉPARATION DE 6-(2-HYDROXY-2-MÉTHYLPROPOXY)-4-(6-(6-((6-MÉTHOXYPYRIDIN-3-YL)MÉTHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE[2020/34]
Entry into regional phase11.05.2020National basic fee paid 
11.05.2020Designation fee(s) paid 
11.05.2020Examination fee paid 
Examination procedure07.05.2020Amendment by applicant (claims and/or description)
11.05.2020Examination requested  [2020/34]
11.05.2020Date on which the examining division has become responsible
29.04.2021Despatch of a communication from the examining division (Time limit: M06)
09.11.2021Reply to a communication from the examining division
08.12.2022Communication of intention to grant the patent
31.03.2023Fee for grant paid
31.03.2023Fee for publishing/printing paid
31.03.2023Receipt of the translation of the claim(s)
Opposition(s)20.02.2024No opposition filed within time limit [2024/17]
Fees paidRenewal fee
02.11.2020Renewal fee patent year 03
02.11.2021Renewal fee patent year 04
31.10.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
MC17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
LU10.10.2023
BE31.10.2023
CH31.10.2023
[2024/36]
Former [2024/34]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
MC17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
LU10.10.2023
CH31.10.2023
Former [2024/30]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
MC17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
LU10.10.2023
Former [2024/28]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
MC17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/24]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/10]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/08]AT17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/03]AT17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/01]AT17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2023/51]AT17.05.2023
HR17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2023/50]AT17.05.2023
NL17.05.2023
PL17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2023/48]AT17.05.2023
NL17.05.2023
SE17.05.2023
NO17.08.2023
PT18.09.2023
Former [2023/46]PT18.09.2023
Cited inInternational search[A]US2012277247  (MENET CHRISTEL JEANNE MARIE [BE], et al) [A] 1-109* example - *;
 [AD]WO2017011776  (ARRAY BIOPHARMA INC [US]) [AD] 1-109 * example -; claim - *;
 [XPI]WO2018071447  (ANDREWS STEVEN W [US], et al) [XP] 1,107,109 * example - * [I] 1-109
by applicantWO2017011776
 US2017096425
    - G. D. FASSMAN, Handbook of Biochemistry and Molecular Biology, CRC Press, (19760000), vol. 1, pages 305 - 347
    - The Peptides: Analysis, Synthesis, Biology, Academic Press, (19810000), vol. 3
    - The Handbook of Pharmaceutical Excipients, American Pharmaceutical Association
    - Pharmaceutical Dosage Forms: Tablets, vol. 1-3
    - Pharmaceutical Dosage Forms: Parenteral Medications, vol. 1-2
    - Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, Inc., vol. 1-2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.